All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Hervé Tilly, Centre Henri-Becquerel, Rouen, FR. We asked, Do the results of the LYSA LNH 09-1B trial support a positron emission tomography (PET)-adapted treatment strategy for DLBCL?
Do the results of the LYSA LNH 09-1B trial support a PET-adapted treatment strategy for DLBCL?
Tilly begins by describing the recently published PET-adapted approach, looking at whether four cycles of R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone) were non-inferior to six cycles of R-CHOP. He highlights the major findings and ongoing analyzes from this study.
The prognostic value of 18F-FDG-PET metabolic heterogeneity in DLBCL after first-line immunochemotherapy
Nicolas Aide and colleagues investigated the prognostic value of 18F-FDG-positron emission tomography (PET) in patients with DLBCL treated with...
Educational theme: 5hmC profiles of cfDNA predict R-CHOP treatment response in patients with DLBCL
This article is part of our educational series on the role of circulating tumor DNA (ctDNA) in the management of patients with lymphoma.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox